AlphAIAlphAI — Financial news for AI agents
investing.comSEP 181 min read$ALMR

Why is Alamar Biosciences stock surging today?

Alamar Biosciences (ALMR) stock rose 6.8% to $34.20 in morning trading, continuing a rally since its Q2 2026 earnings report showed 82% revenue growth and a 60% gross margin. Analysts raised price targets (JPMorgan to $35, Stifel to $32, BofA to $31), maintaining Buy ratings. The company's Alzheimer’s Disease Data Initiative partnership also boosted investor interest. The broader market had minimal impact, suggesting the gains are specific to ALMR's strong fundamentals and growth prospects.

Original reporting
investing.com
Published Sep 18, 2026, 1:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 2:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$ALMR
Bullish
medium confidence
Mentioned
$ALMR
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALMRBullishLow
01

Why it matters

The article recaps existing information without introducing new data.

02

Market read

The piece is a post‑earnings price‑action recap with limited trading relevance.

03

What to watch

Potential headwinds from broader market volatility could cap gains.

Relevance 4/10Novelty 2/10Timing: morning trading today

Background

Alamar reported strong Q2 results in August; analysts raised price targets thereafter.

Company-level read

Ticker impact

$ALMRBullishMedium confidence
Context

Stock surged 6.8% in morning trading following Q2 earnings and analyst target raises.

Expected impact

Modest upside potential if buying pressure continues.

Evidence & confidence

Move is driven by prior earnings and target upgrades, not a fresh event.

Market effects

Sector

Highlights continued interest in high‑growth life‑science tools sector.

Regional

Limited to US biotech equities.

Global

Minimal beyond niche biotech investors.

Counterpoint

What could challenge this read

The rally may be overstated given lack of fresh fundamentals.

Key entities

  • Company
    Alamar Biosciences

    Biotech firm focused on proteomics platforms.

Read at source← All news

Related articles

AUG 18
$ALMRMedAI 8/10

Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q2 2026 revenue of $29.4M, up 82% YoY, with gross margin at 60%. Consumables rose 147% to $15.5M and instrument revenue rose 35% to $7.8M. Net loss was $13.2M. Cash was $256.3M. Full-year 2026 revenue guidance is $116M to $120M and management targets 100+ new instruments.

fool.com7 min
AUG 11
$ALABHighAI 9/10

Alamar Biosciences Shares Rise 18% After Second-Quarter Revenue Jumps 82% Year-Over-Year

Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.

ibtimes.com.au6 min
AUG 10
$ALMRHigh

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance FREMONT, Calif.--August 10, 2026 (GLOBE NEWSWIRE)—Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detectio

SEC EDGAR 8-K4 min
JUL 15
$ALMRMed

Alamar Hits A High Note On Alzheimer's Buzz

Alamar Biosciences (ALMR) shares rose 7.3% to a 52-week high of $28.42 after the company said its NULISA platform will be featured in more than 140 presentations at the Alzheimer’s Association International Conference, according to the company. The article notes no earnings or analyst action and contrasts weaker moves at peers like TMO and ILMN.

yahoo.com4 min